M2 Archive: Preview
You haven't logged in. If you have archive credits in your account, please log in now to use them. If not, you can buy credits in our shopping area.
BioArctic and Bristol Myers Squibb finalise global licence deal for Alzheimer's antibody programme
Swedish research-based biopharma company BioArctic AB (STO:BIOA-B) and US-based Bristol Myers Squibb (NYSE:BMY) have completed the global licence agreement for BioArctic's PyroGlutamate-amyloid-beta (PyroGlu-A?) antibody programme following US Federal Trade Commission clearance, BioArctic...
If you want to view the full text of this story, you must first purchase archive credits. Return to Archives
New Search